NEUROENDOVASCULAR COIL MARKET OVERVIEW AND DEFINITION

Global Neuroendovascular Coil market was valued at USD 1047.66 Mn. in 2024, and is expected to reach USD 1713.14 Mn. by 2032, reflecting a CAGR of 6.34 % over the forecast period (2025-2032)

The neuroendovascular coil market represents a critical part of the neurointervention space, specifically for treating intracranial aneurysms and arteriovenous malformations (AVMs). Coils are inserted via minimally invasive catheter-based procedures to promote clot formation in the aneurysm sac, which reduces the risk of rupture. Over the past decade, given the undeniable improvement in both efficacy and safety of endovascular therapy (compared to traditional neurosurgical clipping), the market's taste has shifted to favor endovascular procedures- largely driven by the reduced downtime and lower procedural risk for patients.

According to the Brain Aneurysm Foundation it is estimated that 6.5 million people in the United States have an unruptured brain aneurysm, with approximately 500,000 deaths annually attributed to ruptured aneurysms, which heightens demand for neuroendovascular coils especially considering the trend of many patients with AVMs and any other intracranial vascular malformations. Compounding the growing demand is the global rise of the geriatric population- which is expected to increase from around 900 million persons over the age of 60 in 2015 to about 1.6 billion by 2050 as per WHO- as older persons are also associated with increased risk of developing cerebrovascular malformations.

Furthermore, the American Stroke Association states that strokes are the second leading cause of death worldwide, and numerous ischemic strokes are caused by aneurysm rupture or AVMs (arteriovenous malformations) that can typically be treated through embolization with coils. In Europe, ESMINT (European Society of Minimally Invasive Neurological Therapy) has reported a 20% to 25% annual increase in endovascular procedures, demonstrating the pace of clinical integration.

Technological innovations are yielding new detachable coils, bioactive coils, and hydrogel coated coils, which will enhance efficacy, minimize recurrence, and enhance long-term outcomes for patients. Medical device companies are also investing in making new microcatheters compatible with existing technologies and improving coil visibility under fluoroscopy.

Internationally, growth in the ambulatory care setting, increased use of advanced imaging to support diagnoses, and favorable clinical guidelines that favor coiling over clipping in clinical situations support the clinical acceptance of the procedure. Emerging economies will continue to expand accessibility to healthcare, investment in care associated with strokes and aneurysms, and enhancements in patient awareness will allow for new potential.

MARKET DYNAMICS

Market Drivers

Rising Prevalence of Intracranial Aneurysms and Stroke Cases

The growing cases of aneurysms and stroke-related complications are one of the key factors propelling the neuroendovascular coil market. According to the Brain Aneurysm Foundation, 1 in 50 people in the United States have an unruptured aneurysm, and roughly 30,000 ruptures occur every year. According to the World Stroke Organization, ischemic and hemorrhagic strokes account for more than 12 million cases a year worldwide. The demand for endovascular coiling procedures is on the rise for a range of reasons, with many minimally invasive embolization procedures increasingly becoming the standard of care for the management of aneurysms and arteriovenous malformations (AVM), leading to an uptick in coil purchases. Additionally, the rise in public awareness and the increasing availability of advanced imaging technologies (such as CTA and MRA) that facilitate earlier diagnosis will continue to increase the number of patients eligible for coiling.

Technological Advancements in Coil Design and Delivery Systems

The progression of coil technology has significantly improved procedural results and physician confidence. Advancements like hydrogel-coated coils, bioactive coils and ultra-soft detachable coils have led to advantages such as improved aneurysm filling and lower rates of recurrences. In one clinical study, hydrogel-coated coils had a 40% lower recurrence rate than bare platinum coils (published in Neurosurgery). Moreover, the delivery systems have improved in their ability to navigate awkward catheter routes with better radiopacity and support of detachment (avoid detuning!). This is allowing more application in developed and emerging healthcare markets.

Market Restraint

High Procedure Costs and Limited Access in Low-Income Regions

The high-cost procedures and limited access in low-income and underserved areas of the world are likely the largest constraints limiting the growth of the neuroendovascular coil market in the coming years. Neuroendovascular coiling is a costly and resource-intensive procedure that requires robust infrastructure, skilled interventional neuroradiologists, expensive technology, and constant access to high-fidelity imaging. In developed nations such as the U.S. and Germany, the average cost of a single coiling procedure exceeds $20,000–$30,000, which often includes device cost, hospital stay, imaging, and post-operative care. While these expenses may be partially covered under insurance in high-income countries, such financial backing is rarely available in developing nations. In addition, low- and middle-income countries are plagued by systemic issues, including a lack of trained professionals, limited centers that provide neurointervention, and inadequate integration of stroke care into public health systems. The World Health Organization suggests that more than 70% of stroke deaths happen in low- and middle-income countries with little or no access to advanced endovascular therapies. Across Africa and parts of South Asia, if rural hospitals offer any stroke procedures at all, they are limited by not having essential resources such as digital subtraction angiography labs, making true neuroendovascular procedures impossible.

Market Opportunity

Expansion of Neurointervention Centers in Emerging Economies

The neuroendovascular coil market has a tremendous opportunity for growth through the establishment of neurointervention sites in developing economies across India, Brazil, Indonesia, and in certain areas of the Middle East and Africa. These economies are already seeing large rates of investment in health care, government-initiated programs for disease management related to stroke, and the appeal for minimally invasive interventions in neurosurgery. The World Bank states that healthcare spending growth, over 6% a year, is occurring in emerging markets, and it is possible these markets are growing at a rapid pace of growth than within developed countries. The healthcare market in India alone is projected to reach $372 billion by 2025 with the help of public private investment and models such as Ayushman Bharat. These regions face a greater burden of cerebrovascular diseases. As example, India's current incidence of stroke is 119–145 events per year per 100,000 people, while the detection of intracranial aneurysms is rapidly increasing, and is the result of increased access to imaging diagnostics. This trend is leading to further investments in advanced tertiary hospitals and dedicated units for neurovascular diseases, which will increase the demand for products such as embolization coils and trained professionals. These developing economies will increasingly become attractive geographical targets for many global manufacturers as healthcare space improves, clinical awareness is higher, and a diverse market pool is available. The partnerships with local distributors, building out their training programs, applying various priced products to meet the market's needs is crucial for capitalizing on such a large, unrecognized, and unserved population.

Market Trends

Adoption of Hydrogel-Coated and Bioactive Coils for Enhanced Outcomes

A revolutionary shift in the neuroendovascular coil market is the trend towards the use of hydrogel-coated and bioactive embolization coils because of the ability to occlude an aneurysm or arteriovenous malformation (AVM) and the lower recurrence rate when compared to bare platinum coils. These advanced coils have been developed to swell when they come into contact with blood and are able to occlude the aneurysm upon filling it and ultimately promote neointimal healing. There are clinical studies that prove hydrogel-coated coils can reduce the recurrence of aneurysm by up to 40% when compared to standard coils. The HEAT study showed in its 18-month follow-up there was statistically significant improvement in occlusion stability when using hydrogel-enhanced technology. Bioactive coils, with an embedded material (for PGLA coils, polyglycolic/polylactic acid) stimulate an enhanced biological response, which is even less favorable for re-treatment.

This trend is fast becoming popular among neurointerventionalists in high-volume centers, especially in North America, Europe and Japan. ESMINT and SNIS report that over 65% of complex wide-neck aneurysms in Europe are now treated with some form of next-gen coils or adjunctive devices. In addition, there is a trend towards bundling these technologies with delivery systems to enhance the workflow process and minimize intraoperative complications.

SEGMENTATION ANALYSIS

By Type Analysis

The Gold Standard and Volume Leader in Neuroendovascular Aneurysm Treatment

The largest share of the neuroendovascular coil market belongs to bare platinum coils, which are used nearly universally in the clinical setting, are affordable (low cost compared to others), and that virtually every interventional neuroradiologist is accustomed to using them. Bare platinum coils were first available just as intervention neuroradiology came into the clinical practice around the early 1990s. Bare platinum coils are made of platinum only and are excellent in radiopacity, deployment flexibility during coil placement, and provide a familiar environment when treating aneurysms. Despite the rise of new materials based on coating and bioactive technology, bare platinum coils are still the first choice in many situations, especially in simple aneurysm morphologies or when cost is a major decision-making factor. 

As supported by information from the Journal of NeuroInterventional Surgery (JNIS), over 60% of all coiling of aneurysms performed globally are still using bare platinum coils. This use of bare platinum coils is highest in developing markets (eg. South America- Brazil, India and Eastern Europe) and where availability, access and/or cost of a new advanced technology could be a challenge for the patient and provider. Bare platinum coils perform as expected, easy to detach and are compatible with the majority of micro-catheters. Manufacturers still produce soft coils and coil framing features in the bare segment of coils. Mega - hospital chain groups and the public health care systems of Brazil, India, and Eastern Europe have a preference for bare coils contained in purchase tenders and bulk purchases due to cost. Bare platinum coils have recurrence rates that can be slightly higher than coils that offer a hydrogel coating and more. When used by an experienced user (interventional neuroradiologist) in most of these standard cases bare platinum coils remain as the 'standard of care' and the largest share by volume.

By Application Analysis

Fastest Growing Frontier in Neuroendovascular Coiling Fueled by Imaging Advances and Global Procedural Expansion

Arteriovenous malformation (AVM) is quickly becoming the fastest growing application segment of the neuroendovascular coil market, due to increasing detection rates, improved neuroimaging as well as expanding interventional capability. Typically, AVMs are tangled web of blood vessels that cause disruption to the normal circulation in the brain and, when ruptured can produce life-threatening hemispheric hemorrhages. While traditional treatments have remained surgery and stereotactic radiosurgery, endovascular embolization has emerged as both a standalone, as well as an add-on technique, to begin or improve the outcome of bleeds originating from deep structures of the brain with lesions that are deemed inaccessible or inoperable.

With improved imaging technologies and expanded screening protocols exponentially better detection routes, the rate of AVMs detected globally over the past decade has invariablly increased by over 25% based on American Association of Neurological Surgeons (AANS) registries, especially using Catheter Angiography, which is typically the routine first step in any treatment algorithm to evaluate the patient for lesions. In many cases, endovascular treatment coiling for AVM will be combined with liquid embolic agents which controls the flow preoperative definitive surgical or stereotactic radiation treatment of AVMs, ranking coiling play a major role in multi-modal treatments for AVM. This segment exhibits the fastest growth pattern in the Asia-Pacific and Latin America region, which is where interventional radiology centers are being built - with procedural capability rapidly expanding. In highly developed markets, technological advancements in catheterization processes and micro coil design are expanding the subset of treatable AVM. As minimally invasive neurointerventions become more refined and AVM awareness rises among neurologists and neurosurgeons, the use of neuroendovascular coils in this segment is expected to accelerate significantly.

REGIONAL INSIGHTS

North America Dominant Force in the Global Neuroendovascular Coil Market

North America is leading the way with respect the neuroendovascular coil market, holding nearly 38% of the global market share in 2024. This large share is driven by the healthcare infrastructure in the North America, reimbursement options and prevalence of cerebrovascular diseases, such as cerebral aneurysms and arteriovenous malformations (AVMs). The US has numerous neurointerventional centers with available imaging modalities and growing number of neurointerventional specialists. According to the American Heart Association, stroke and other neurovascular diseases affect nearly 795,000 patients in the US each year, resulting in a high demand for minimally invasive procedures such as coil embolization. There has been significant investment in research and development in North America, allowing more efficient adoption of novel coil technologies such as hydrogel coated coils and bioactive coils. In addition, advantageous government policies and increasing awareness of cerebrovascular disease also help to influence the sector. The presence of many large global manufacturers with established sales and distribution channels further cements the region’s role in the neuroendovascular coil market as the largest and most mature.

Asia-Pacific Fastest Growing Market Fueled by Rising Stroke Burden and Expanding Neurointerventional Access

Asia-Pacific is the fastest growing region in this market driven by rapid urbanization, increasing healthcare spending, and greater access to advanced neurointerventional procedures. The market in this region is expected to expand at a rapid pace during the forecast period. There are increasing levels of investment in healthcare infrastructure, improved awareness of neurovascular disease, and targeted workforce development in skilled professions in various countries in this region, such as China, India, Japan, and South Korea.  According to WHO data, the stroke incidence in Asia-Pacific is the highest in the world at over 15 million new cases annually, thus creating an urgent need for effective neurovascular interventions. Improved reimbursement systems, increased government investments into upgrading tertiary care centers, and advancements in therapies needed in neurointerventional practices are also fuelling market growth. The upsurge in specialized neurointerventional units and further availability of innovative products such as coils designed for complex aneurysms, and AVMs, indicates a rapidly evolving market. Market players are in the process of establishing partnerships and beginning local manufacturing to capture this opportunity.

KEY INDUSTRY DEVELOPMENTS:

• January 2025, Kaneka Corporation (Tokyo), a healthcare company, announced the purchase of a 96.8% stake in EndoStream Medical Ltd. (Or Akiva, Israel), a medical device start-up. The purchase is part of Kaneka's strategy to grow its healthcare business and expand its share of the neurovascular treatment market.
• May 2023, Cerenovus, Inc. (a J&J MedTech company) announced the U.S. commercial launch of the company's next neurovascular innovation, the CEREPAK Detachable Coils, and confirmed that the first patient cases have been successfully performed.

NEUROENDOVASCULAR COIL MARKET REPORT SCOPE & SEGMENTATION

MARKET REGIONAL COVERAGE           

• North America (United States, Canada, Mexico)
• Europe (Germany, Italy, United Kingdom, France, Russia, Hungary, Netherland, Ireland, Austria, Rest of Europe)
• Asia Pacific (China, India, Japan, South Korea, Australia, New Zealand, Thailand, Singapore, Philippines, Indonesia, Vietnam, Rest of Asia Pacific)
• Middle East and Africa (South Africa, Israel, UAE, Iran, Kuwait, Iraq, Saudi Arabia, Qatar, Rest of Middle East and Africa
• South America (Brazil, Argentina, Rest of South America)

NEUROENDOVASCULAR COIL MARKET ACTIVE PLAYERS

• Penumbra, Inc
• Kaneka Medical Europe N.V.
• Stryker
• Lepu Medical Technology (Beijing) Co.,Ltd
• Balt
• NeuroSafe Medical Co., Ltd.
• Johnson & Johnson
• Boston Scientific Corporation
• Medtronic
• Terumo Corporation

*Disclaimer: The active players are listed in no specific order.